A. Suvorov

发表

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2017, Leukemia & lymphoma.

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

M. Dimopoulos, A. Palumbo, A. Jakubowiak, 2017, British journal of haematology.

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

A. Palumbo, A. Jakubowiak, D. Siegel, 2017, Blood Cancer Journal.

Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)

S. Russell, H. Goldschmidt, M. Dimopoulos, 2015 .

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

A. Mead, P. Ganly, R. Mesa, 2017, The Lancet. Haematology.

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance

L. Rundo, E. Sala, V. Gnanapragasam, 2021, European Radiology.

A systematic review and meta‐analysis of placebo effect in clinical trials on chronic prostatitis/chronic pelvic pain syndrome

D. Enikeev, G. Russo, M. Taratkin, 2022, The Prostate.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015, The New England journal of medicine.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, The Lancet. Oncology.

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.

A. Mead, P. Ganly, R. Mesa, 2016 .

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia

A. Mead, P. Ganly, R. Mesa, 2016 .

Safety and Efficacy of Different Anticoagulant Doses for Patients with COVID-19 in the ICU: A Systematic Review and Meta-Analysis

D. Bourgeois, S. Rachina, N. Dyatlov, 2023, Journal of clinical medicine.

Application of photodynamic therapy in complex treatment of purulent diseases of the hand

A. Suvorov, G. Melkonyan, Y. Chepurnaya, 2020, Biomedical Photonics.

Cuffless Blood Pressure Measurement Using a Smartphone-Case Based ECG Monitor with Photoplethysmography in Hypertensive Patients

Aleksandr Suvorov, Hugo Saner, Stefano Omboni, 2021, Sensors.

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2016 .

Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials.

J. Ho, L. Rosiñol, D. White, 2017 .

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2015 .

Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).

A. Mead, P. Ganly, A. Vannucchi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

A. Mead, P. Ganly, R. Mesa, 2017, The Lancet. Haematology.

Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2015 .